DXCM
DexCom, Inc.NASDAQHealthcare$62.22-0.24%ClosedMarket Cap: $24.27B
As of 2026-04-06
Valuation
P/E (TTM)
29.02
PEG
0.64
P/B
8.76
P/S
5.21
EV/EBITDA
18.51
DCF Value
$32.38
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.1%
Operating Margin
19.6%
Net Margin
17.9%
ROE
32.4%
ROA
13.4%
ROIC
16.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.26B | 62.9% | $323.0M | $267.3M | $0.67 | — |
| FY 2025 | $4.66B | 60.1% | $911.8M | $836.3M | $2.09 | — |
| Q3 2025 | $1.21B | 60.5% | $242.5M | $283.8M | $0.70 | — |
| Q2 2025 | $1.16B | 59.5% | $212.6M | $179.8M | $0.45 | — |
| Q1 2025 | $1.04B | 56.9% | $133.7M | $105.4M | $0.27 | — |
| Q4 2024 | $1.11B | 58.9% | $188.9M | $151.7M | $0.38 | — |
| FY 2024 | $4.03B | 60.5% | $600.0M | $576.2M | $1.42 | — |
| Q3 2024 | $994.2M | 59.7% | $152.0M | $134.6M | $0.34 | — |
| Q2 2024 | $1.00B | 62.4% | $158.0M | $143.5M | $0.35 | — |
| Q1 2024 | $921.0M | 61.0% | $101.1M | $146.4M | $0.36 | — |
| Q4 2023 | $1.03B | 63.5% | $216.9M | $256.3M | $0.62 | — |
| FY 2023 | $3.62B | 63.2% | $597.7M | $541.5M | $1.30 | — |